Status and phase
Conditions
Treatments
About
Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Documented history or considered to be at increased risk of venous thromboembolism
Subjects considered to be at increased risk of bleeding:
Acute bacterial endocarditis
Severe hypertension
Retinopathy
Concomitant use of anticoagulants / antiplatelet agents (including homeopathic drugs) and/or anticipated postoperative need for other reasons than prevention of DVT during the study period.
Primary purpose
Allocation
Interventional model
Masking
367 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal